Related Experiment Videos
Multiple myeloma and chronic lymphocytic leukemia
L Rosen1, R Vescio, J R Berenson
1Department of Veterans Affairs, West Los Angeles, California, USA.
Current Opinion in Hematology
|July 1, 1995
Summary
New insights into multiple myeloma and chronic lymphocytic leukemia treatments are emerging. Advances include stem cell transplantation for myeloma and nucleoside analogues for leukemia, improving patient outcomes.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- Multiple myeloma and chronic lymphocytic leukemia (CLL) are hematologic malignancies with distinct molecular characteristics.
- Understanding these differences is crucial for developing targeted therapies and improving patient prognoses.
Purpose of the Study:
- To review recent advancements in the molecular biology and treatment of multiple myeloma and CLL.
- To highlight novel therapeutic strategies and prognostic indicators for these diseases.
Main Methods:
- Review of current literature on multiple myeloma and CLL molecular biology.
- Analysis of emerging treatment modalities, including stem cell transplantation and pharmacotherapy.
- Evaluation of prognostic markers such as cell surface markers and cytogenetic abnormalities.
Main Results:
- For multiple myeloma, CD34 expression absence aids in functional autografting, with single/double transplants used for high-risk/relapsed cases. Interleukin-6 (IL-6) and bisphosphonates impact tumor growth and skeletal complications.
- For CLL, nucleoside analogues show high response rates. Cell surface markers and cytogenetics identify poor-prognosis patients, while myeloablative therapy remains debated.
Conclusions:
- Advances in understanding molecular pathways offer new treatment avenues for myeloma and CLL.
- Targeted therapies and improved prognostic tools are enhancing patient management and outcomes in these leukemias.